BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ixempra ixabepilone: Additional Phase III data

Data from a subset of 443 triple-negative breast cancer patients in a pooled analysis of 2 Phase III trials (046 and 048) showed that Ixempra plus capecitabine significantly increased progression-free survival vs. capecitabine alone (median 4.2 vs. 1.7...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >